Table 2 Liver pathology score.

From: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

Parameter

BD

CTRL

PEMA-L

PEMA-H

FENO

n

5

10

10

10

7

NAS

0.2 ± 0.2†

7.2 ± 0.2

6.2 ± 0.2

3.9 ± 0.5*

5.7 ± 0.4*

Steatosis

0†

3

3

1.3 ± 0.2*

2.4 ± 0.2*

Lobular inflammation

0.2 ± 0.2†

2.1 ± 0.2

1.2 ± 0.2

1.3 ± 0.4

1.4 ± 0.3

Hepatocyte ballooning

0†

2

2

1.3 ± 0.2*

1.9 ± 0.1

Fibrosis

0.4 ± 0.2†

2.3 ± 0.2

1.6 ± 0.2

1.4 ± 0.2*

1.3 ± 0.3*

  1. Nonalcoholic fatty liver disease activity score (NAS) and fibrosis stage were scored according to the method described by Kleiner et al.63, as outlined in (Supplementary Table 2). Significance was determined using Student’s t-test (†p < 0.05 versus CTRL mice) or Dunnett’s test (*p < 0.05 versus CTRL mice).
Back to article page